证券时报·数据宝统计显示，1月15日有42家香港上市公司进行了股份回购，合计回购2844.54万股，回购 金额9.45亿港元。 | 01317 | 枫叶教育 | 290.20 | 111.73 | 0.385 | 0.385 | 220.37 | | --- | --- | --- | --- | --- | --- | --- | | 01066 | 威高股份 | 18.00 | 99.08 | 5.520 | 5.490 | 2859.04 | | 01497 | 燕之屋 | 15.00 | 92.73 | 6.280 | 6.060 | 92.73 | | 02598 | 连连数字 | 13.00 | 90.95 | 7.150 | 6.930 | 698.04 | | 01600 | 天伦燃气 | 28.00 | 82.09 | 2.930 | 2.910 | 932.08 | | 06831 | 绿茶集团 | 10.60 | 74.33 | 7.120 | 6.960 | 848.83 | | 09959 | 联易融科 | 28.80 | 73.71 | 2.570 | 2.530 | 170.07 ...

Major Events - Giant Bio (02367) received the Medical Device Registration Certificate from the National Medical Products Administration for its recombinant type I α1 collagen and sodium hyaluronate composite solution [1] - Jitu Express-W (01519) plans to subscribe for 226 million H shares of SF Holding and issue 822 million Class B shares to SF Holding [1] - Zijin Mining (02899) signed a cooperation and equity transfer agreement for the Shapingou Molybdenum Mine project [1] - Jiangxi Copper (00358) subsidiary signed an Investment Option Agreement with First Quantum for exploration cooperation in Kazakhstan's mining projects [1] - Derin Holdings (01709) received conditional approval from the CSRC for Derin Securities to provide virtual asset consulting services [1] - GAC Group (02238) subsidiary GAC Trumpchi received 100 million yuan in funding for industrial transformation and development [1] - Juteng International (03336) suspected of a cyber attack and has initiated a comprehensive investigation [1] Operating Performance - China Southern Airlines (01055) increased passenger capacity input by 11.89% year-on-year in December [1] - Air China (00753) reported a 10% year-on-year increase in passenger turnover in December [1] - China Eastern Airlines (00670) saw a 7.61% year-on-year increase in passenger turnover in December [1] - China Metallurgical Group (01618) new contract amount for 2025 is 1,113.6 billion yuan, a decrease of 10.8% year-on-year [1] - ZhongAn Online (06060) projected total original insurance premium income of approximately 35.643 billion yuan for 2025, an increase of 6.66% year-on-year [1] - China General Nuclear Power Corporation (01164) produced a total of 702.5 tons of natural uranium in the fourth quarter [1] - Jiuxing Holdings (01836) reported a 0.8% year-on-year increase in comprehensive income to 388.6 million USD in the fourth quarter [1] - Luoyang Molybdenum (03993) issued a profit warning, expecting annual net profit attributable to shareholders to be between 20 billion and 20.8 billion yuan, an increase of 47.80% to 53.71% year-on-year [1] - Chongqing Iron and Steel (01053) issued a profit warning, expecting a net loss of 2.5 billion to 2.8 billion yuan for 2025 [1] - Huiju Technology (01729) issued a profit warning, expecting annual net profit to increase by approximately 60% to 70% year-on-year [1]

| 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2026.01.15 | 40.00 | 36.100 | 35.440 | 1434.67 | | 2026.01.14 | 40.00 | 35.800 | 35.100 | 1415.00 | | 2026.01.13 | 40.00 | 36.200 | 35.640 | 1433.78 | | 2026.01.12 | 40.00 | 35.500 | 34.500 | 1400.29 | | 2026.01.09 | 40.00 | 34.580 | 34.240 | 1375.96 | | 2026.01.08 | 40.00 | 34.440 | 34.120 | 1371.06 | | 2026.01.07 | 40.00 | 34.680 | 34.300 | 1378.34 | | 2026.01.06 | 40.00 | 34.480 | 33.840 | 1366.93 | | 2026.01.05 | 40. ...

Core Viewpoint - The company, Juzi Biotechnology, announced that its wholly-owned subsidiary, Shaanxi Juzi Biotechnology Co., Ltd., has received a medical device registration certificate from the National Medical Products Administration of China for a recombinant type I α1 collagen and sodium hyaluronate composite solution product [1] Group 1 - The product is primarily composed of recombinant collagen and sodium hyaluronate [1] - It is intended for injection into the dermis to improve the smoothness of the cheek area [1]

巨子生物(02367)公布，2026年1月15日耗资约1434.67万港元回购40万股股份。 ...

智通财经APP讯，巨子生物(02367)公布，2026年1月15日耗资约1434.67万港元回购40万股股份。 ...

格隆汇1月15日丨巨子生物(02367.HK)发布公告，2026年1月15日耗资1434.7万港元回购40万股，回购价 格每股35.44-36.1港元。 ...

表格類別： 股票 狀態： 新提交 公司名稱： 巨子生物控股有限公司 呈交日期： 2026年1月15日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | 證券代號 (如上市) | 02367 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | ...

Core Viewpoint - The company, Giant Bio (02367.HK), has received a medical device registration certificate from the National Medical Products Administration of China for its recombinant type I α1 collagen and sodium hyaluronate composite solution, marking a significant advancement in its product offerings [1] Group 1: Product Approval - The product is the world's first recombinant collagen and sodium hyaluronate composite solution approved for improving cheek smoothness, indicating a pioneering position in the market [1] - The approval was achieved through a joint review of device and drug assessments, showcasing the company's robust regulatory compliance [1] Group 2: Market Expansion - The successful approval of this product expands the company's product matrix and highlights its ongoing technological research and industrialization capabilities [1] - The company aims to promote the product's market launch and distribution, leveraging a diverse product portfolio, comprehensive channel network, and refined brand management to meet consumer demands in various scenarios [1] - This development is expected to inject new growth momentum into the company's business in the skin rejuvenation sector, reinforcing its leading market position in health and beauty [1]

Core Viewpoint - The company has received a medical device registration certificate from the National Medical Products Administration of China for its recombinant type I α1 collagen and sodium hyaluronate composite solution, marking a significant milestone in its product development and market expansion [1] Product Development - The product is the world's first recombinant collagen and sodium hyaluronate composite solution approved for improving cheek smoothness, showcasing the company's innovative capabilities [1] - This approval follows the successful registration of the recombinant type I α1 collagen freeze-dried fiber, further expanding the company's product matrix [1] Market Strategy - The company aims to steadily promote the product's market launch and distribution, leveraging a diverse product portfolio, comprehensive channel network, and refined brand management [1] - The introduction of this product is expected to inject new growth momentum into the company's business development in the skin rejuvenation sector [1]